Juha-Pekka Erälinna

Author

Juha-Pekka Erälinna

Also Known As

J P Erälinna, J. -P. Erälinna, J. P. Eralinna, J. P. Erälinna, J.-P Erälinna, J.-P. Erälinna, J.-P. Erälinna, J.P. Eralinna, J.P. Erälinna, JUHA-PEKKA ERÄLINNA

Publications

2.7K

Citations

H-Index

Concepts

All Affiliations

University of Turku Rigshospitalet Alexion Pharmaceuticals (United States)National Hospital Organization Hanamaki Hospital Stanford University

About

Juha-Pekka Erälinna is an author at University of Turku specializing in medicine, immunology, and neuroimmunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	1.4K
2	Immunology	8	8	621
3	Neurology	4	4	535
4	Allergy	2	2	50
5	Cell Biology	1	1	35

Juha-Pekka Erälinna

Publications

2.6K

Citations

H-Index

Page 1

	Year	Citations
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study James F. Howard, Kimiaki Utsugisawa, Michael Benatar, The Lancet Neurology Multicentre StudyPharmacologyMedicineMyasthenia GravisNeuromuscular Blockade	2017	745
PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS G. Francis, Richard AC Hughes, John King, DIAL (Catholic University of Leuven)	2001	472
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension Raju Kapoor, Pei‐Ran Ho, Nolan Campbell, The Lancet Neurology Disease ProgressionNeurological DisorderImmunologyClinical TrialsNeurology	2018	327
Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS Ludwig Kappos, Anthony Traboulsee, Cris S. Constantinescu, Neurology	2006	255
Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial Per Soelberg Sørensen, Jan Lycke, Juha-Pekka Erälinna, The Lancet Neurology Relapsing-remitting Multiple SclerosisSimcombin StudyImmunologyClinical TrialsNeurological Progress	2011	116
Ambient Air Quality and Occurrence of Multiple Sclerosis Relapse Mervi Oikonen, Mikko Laaksonen, Pekka Laippala, Neuroepidemiology	2003	105
Neutralizing antibodies reduce MxA protein induction in interferon- beta-1a-treated MS patients Anna-Maija Vallittu, Markus Halminen, Jutta Peltoniemi, Neurology	2002	80
Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension Renato Mantegazza, Gil I. Wolfe, Srikanth Muppidi, Neurology	2020	74
Semliki Forest virus infects mouse brain endothelial cells and causes blood-brain barrier damage Merja Soilu‐Hänninen, Juha-Pekka Erälinna, Veijo Hukkanen, Journal of Virology Endothelial CellsImmunologyViral PathogenesisBlood-brain Barrier DamageVirus Transmission	1994	68
Temporal relationship between environmental influenza A and Epstein–Barr viral infections and high multiple sclerosis relapse occurrence Mervi Oikonen, Mikko Laaksonen, Ville Aalto, Multiple Sclerosis Journal	2011	62

Page 1